User profiles for Dave L Dixon

Dave L. Dixon

Professor and Chair, Virginia Commonwealth University School of Pharmacy
Verified email at vcu.edu
Cited by 4734

[HTML][HTML] Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19

…, A Vecchié, L Dagna, K Martinod, DL Dixon… - Nature Reviews …, 2021 - nature.com
Coronavirus disease 2019 (COVID-19) is a clinical syndrome caused by infection with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients with severe disease …

2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association …

…, V Bittner, LPC Brewer, SH Demeter, DL Dixon… - Journal of the American …, 2023 - jacc.org
Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients
With Chronic Coronary Disease” provides an update to and consolidates new evidence …

The cardiometabolic health alliance: working toward a new care model for the metabolic syndrome

…, KK Collins, S Cook, NV Dhurandhar, DL Dixon… - Journal of the American …, 2015 - jacc.org
The Cardiometabolic Think Tank was convened on June 20, 2014, in Washington, DC, as a
“call to action” activity focused on defining new patient care models and approaches to …

2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology …

…, K Amancherla, LL Davis, A Deswal, DL Dixon… - Journal of the American …, 2023 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Collaborative drug therapy management and comprehensive medication management―2015

…, S Benavides, EA Chester, DL Dixon… - … : The Journal of …, 2015 - Wiley Online Library
The American College of Clinical Pharmacy ( ACCP ) previously published position statements
on collaborative drug therapy management ( CDTM ) in 1997 and 2003. Since 2003, …

Effects of sodium‐glucose cotransporter 2 inhibitors on 24‐hour ambulatory blood pressure: a systematic review and meta‐analysis

…, R Brown, S Carbone, A Abbate, DL Dixon - Journal of the …, 2017 - Am Heart Assoc
Background Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are a novel class of
antihyperglycemic agents that improve glycemic control by increasing glycosuria. Additional …

Interleukin‐1 blockade inhibits the acute inflammatory response in patients with ST‐segment–elevation myocardial infarction

…, MG Del Buono, A Schatz, C Vo, DL Dixon… - Journal of the …, 2020 - Am Heart Assoc
Background ST ‐segment–elevation myocardial infarction is associated with an intense acute
inflammatory response and risk of heart failure. We tested whether interleukin‐1 blockade …

Select Drug-Drug Interactions With Direct Oral Anticoagulants: JACC Review Topic of the Week

BS Wiggins, DL Dixon, RR Neyens, RL Page… - Journal of the American …, 2020 - jacc.org
Millions of individuals in the United States require long-term treatment with an oral anticoagulant.
For decades, vitamin K antagonists were the only oral option available; however, they …

Systolic blood pressure time in target range and cardiovascular outcomes in patients with hypertension

N Fatani, DL Dixon, BW Van Tassell, J Fanikos… - Journal of the American …, 2021 - jacc.org
Background Standard blood pressure control metrics may not account for fluctuations in blood
pressure over time. Objectives This study sought to estimate the independent association …

Intensive versus standard blood pressure control in SPRINT-eligible participants of ACCORD-BP

LF Buckley, DL Dixon, GF Wohlford IV… - Diabetes …, 2017 - Am Diabetes Assoc
OBJECTIVE We sought to determine the effect of intensive blood pressure (BP) control on
cardiovascular outcomes in participants with type 2 diabetes mellitus (T2DM) and additional …